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INTRODUCTION
Cervical cancer is the third most female malignancy
in the world and the second most in Indonesia; The
Globocan Project in 2012 stated that the incidence
of cervical cancer was 20928 cases and mortality
rate was 9498 cases annually.1,2 Data from several
hospitals in Jakarta reported the 5-year survival
rate of cervical cancer stage I, II, II, and IV were
50%, 40%, 20%, and 0% respectively.3 Both the
incidence and mortality rate of cervical cancer
were well-correlated with cervical cancer
prevention program; particularly the precervical
cancer lesion triage program such as visual
inspection of acetic acid, cytology-based screening,
colposcopy, and optoelectric.4 The high incidence
of cervical cancer in several developing countries,
especially in Indonesia,  was the result of
inadequacy of screening programs in detecting the
cervical cancer in its initial process, precervical
cancer lesion. On the contrary, cytology-based
screening have already been well established and
organized to be a routine screening program of
Abstract
Objective: To investigate the accuracy of liquid-based cytology,
HPV DNA test, and the combination of liquid-based cytology
and HPV DNA test, compared to histopathology as the gold
standard of precervical cancer lesion screening.
Methods: This was a cross-sectional study. The medical records of
patients who came to the Women’s Health Clinic of Dr. Cipto
Mangunkusumo Hospital during the period of July 2013 to
December 2015 were evaluated.
Results: The high risk type HPV DNA is detected in 76% CIN 1,
88.46% CIN 2, and 84.21 CIN 3 in histopathology results. The
accuracy of liquid-based cytology; sensitivity 88.54%, specificity
35.71%, PPV 75.89%, and NPV 57.69%. The accuracy of HPV DNA;
sensitivity 81.25%, specificity 78.57%, PPV 89.66%, and NPV
64.71%. The accuracy of combination: sensitivity 94.79%, speci-
ficity 35.71%, PPV 77.12%, and NPV 75%.
Conclusion: The addition of HPV DNA test increased the sensiti-
vity from 88.54% to 94.79% because of decreasing of false
negative of liquid-based cytology. This thing has showed that the
combination of liquid-based cytology and HPV DNA test could the
one of the option of precervical cancer lesion screening method,
especially in secondary or tertier health center in Indonesia.
[Indones J Obstet Gynecol 2017; 5-4: 241-245]
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Abstrak
Tujuan: Diketahuinya angka akurasi liquid-based cytology, DNA
HPV, dan kombinasi keduanya dibandingkan dengan hasilhistopatologi.
Metode: Penelitian ini merupakan penelitian potong lintang denganjumlah sampel 138 subjek pada Juli 2013 - Desember 2015 di RS Dr.
Cipto Mangunkusumo Kencana.
Hasil: DNA HPV tipe risiko tinggi terdapat pada 76% NIS 1, 88,46%
NIS 2, dan 84,21% NIS 3 pada hasil histopatologi. Didapatkanakurasi pemeriksaan liquid-based cytology; sensitivitas 88,54%,
spesifisitas 35,71%, NPP 75,89%, dan NPN 57,69%. Akurasi
pemeriksaan DNA HPV; sensitivitas 81,25%, spesifisitas 78,57%,NPP 89,66%, dan NPN 64,71%. Sementara akurasi kombinasi
keduanya adalah sensitivitas 94,79%, spesifisitas 35,71%, NPP
77,12%, dan NPN 75%.
Kesimpulan: Penambahan pemeriksaan DNA HPV meningkatkanangka sensitivitas dari 88,54% menjadi 94,79% karena turunnya
angka negatif palsu pemeriksaan LBC. Hal ini menjadikan kombinasi
pemeriksaan liquid-based cytology dan DNA HPV dapat menjadipilihan metode penapisan lesi pra-kanker serviks terutama pada
fasilitas kesehatan sekunder ataupun tersier di Indonesia.
[Maj Obstet Ginekol Indones 2017; 5-4: 241-245]
Kata kunci: DNA HPV, lesi prakanker serviks, liquid-based cytology,
penapisan lesi prakanker serviks, uji akurasi
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precervical cancer lesion screening program in
some developed countries. Cytology-based
screening has already been modified to liquid-
based cytology in which aimed to lower the un-
satisfactory result and improve the sensitivity.7
Previous studies showed that the sensitivity
of liquid-based cytology varied from 76.2% to
96.24%.5,6
The HPV DNA test has a high sensitivity as a
precervical cancer screening tool, especially in the
above 30-year old female population, there of in
several developed countries the HPV DNA test is
used as a triage screening tools.7,8 Some studies
reported that HPV DNA test sensitivity was ranged
94.7% to 97.4%.7,9 The additional HPV DNA test
was alleged to be the co-testing which could be
combined to the cytology screening in order to
increase the sensitivity of precervical cancer
screening program on account of its high
sensitivity. The co-testing of liquid-based cytology
and HPV DNA test intended to increase the
sensitivity and lower the false negative rate in
cytology-based screening tool. Furthermore, not
with standing the high cost of both liquid-based
cytology and HPV DNA test, this co-testing was
allegedly reported to increase the sensitivity which
crucial and important parameter for screening tool.
To date,  there were no data and report
corresponded to this co-testing of liquid-based
cytology and HPV DNA test in Indonesia. This study
is expected to be the reference for some options in
precervical cancer screening tool, especially in
secondary or tertiary health care center.
METHODS
This cross-sectional study was carried out at the
Women’s Health Center Dr. Cipto Mangunkusumo
Hospital, Jakarta from July 2013 to December
2015. We collected data from medical records of
patients who went to the Women’s Health clinic of
Dr. Cipto Mangunkusumo Hospital from other
health center referral or those who came by
her own will to have a precervical cancer
lesion screening program. The inclusion criteria
were 20 - 65 years old and those who were
sexually active. These patients were offered the co-
testing of liquid-based cytology and HPV DNA test,
which continued with colpos-copy. If the result of
colposcopy was normal, they would not undergo
biopsy (LEEP or LLETZ); meanwhile those with
abnormal colposcopy results would undergo
biopsy (LEEP or LLETZ). The cervical cancer result
of histopathology was excluded in this study.
The data were run into sensitivity, specificity,
positive predictive value (PPV), and negative
predictive value (NPV) analysis for each
examination consisting of liquid-based cytology,
HPV DNA test, and histopathology. This analysis
was performed through SPSS24.0 for Windows©.
RESULTS
There were 138 subjects recruiting to this study.
All of subjects were ranged from 22 - 65 years old
with mean age was 41.96 years old. Of these 138
subjects, 55 patients (39.9%) were parity of 3.
Table 1 pointed out that the results of liquid-
based cytology of LSIL is at the most proportion
sample with 33.3% and ASCH is the least propor-
tion in this study with 3.6%. Aside from that, high-
risk type HPV DNA was detected in 63% samples
where it consisted of single DNA was detected in
34.1%, combination of high risk and low risk type
with 1.4%, and the combination of high risk type
with 27.5%; in which these high risk type HPV
DNA, type 16 was the most proportion with 28.1%,
followed by type 18 and type 52 (23.97% and
17.36 respectively).
Table 1. Characteristic of Liquid-Based Cytology, HPV
DNA Test, and Histopathology Result
Examination N (%)
Liquid-Based Cytology
Negative 26 (18.8)
ASCUS 29 (21)
LSIL 46 (33.3)
HSIL 32 (23.2)
ASCH 5 (3.6)
HPV DNA Test
Negative / Not Detected 44 (31.9)
Low Risk Type 7 (5.1)
High Risk Type
 Single 47 (34.1)
 Combination of High Risk - Low risk 2 (1.4)
 Combination of High Risk 38 (27.5)
Histopathology
CIN1 50 (36.2)
CIN2 26 (18.8)
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CIN3 19 (13.8)
Non CIN 43 (31.2)
Total 138 (100)
Of 50 samples of CIN 1, high risk HPV DNA was
detected in 38 samples (76%); meanwhile of 26
samples of CIN 2, high risk HPV DNA was positive
in 88.46%; and of 19 samples of CIN 3, there was
84.21% high risk HPV DNA (Table 2). Furthermore,
high risk HPV DNA were detected in 62.07% of
ASCUS, 67.4% of LSIL, 84.38% of HSIL, and100%
of ASCH.
Table 2. Charateristic of HPV DNA Test and Histopa-
thology
DNA HPV
Not De-
tected
Low
Risk
High
Risk
Total
Histopathology
CIN 1 8 4 38 50
CIN 2 3 - 23 26
CIN 3 1 2 16 19
Non CIN 32 1 10 43
Total 44 7 87 138
The accuracy and screening parameter of liquid-
based cytology, HPV DNA test, and co-testing of
liquid-based cytology and HPV DNA were analyzed
by 2 x 2 table and resulted the accuracy parameter:
sensitivity, specificity, positive predictive value,
and negative predictive value. This study has
results of sensitivity of liquid-based cytology, HPV
DNA, and co-testing of liquid-based cytology and
HPV DNA as 88.54%, 81.25%, and 94.79%
respectively; and positive predictive value as
75.89%, 89.66%, and 77.12% respectively. On
the other hand, there were poor specificity results
(35.71%) in both liquid-based cytology and co-
testing (Table 3).
DISCUSSION
From the diagnostic value we obtained, we con-
cluded that the highest sensitivity is the co-testing
of liquid-based cytology and HPV DNA (94.79%);
compared to single screening method of liquid-
based cytology (88.54%) and HPV DNA (81.25%);
even though the sensitivity of 88.54% is decent as
a precervical cancer screening tool. This sensitivity
of liquid-based cytology was in accordance with
other study conducted by Oh et al in 2002 and
Beerman et al in 2009 which stated that the
sensitivity of liquid-based cytology was 92% and
96.24%, respectively.5,10 There was a wide range
sensitivity of cytology-based screening as this
procedure was operator-dependent, cytologist and
pathologist. In this study, the operator bias was
minimalized as the cytology sample was collected
by the same experienced doctor. The poor speci-
ficity in liquid-based cytology (35.71%) is not
consistent compared to the previous studies
because the high false positive rate in this study
which might be caused by error in interpreting the
cytology result and the small proportion of non CIN
result compared to CIN result. Nevertheless, this
result not correlated to the purpose of this study
which aims for screening the precervical cancer
lesion as the specificity corresponds to the
Table 3. Accuracy of Liquid-Based Cytology, HPV DNA, and Co-Testing as Screening Tool
Diagnostic Parameter Pre Cervical Cancer Lesion Screening
LBC HPV DNA LBC and HPV DNA
Sensitivity 88.54%(95% CI 80.42 - 94.14 %)
81.25%
(95% CI 72 - 88.49 %)
94.79%
(95% CI 88.26 - 98.29%)
Specificity 35.71%(95% CI 21.55 - 51.97%)
78.57%
(95% CI 63.19 - 89.7%)
35.71%
(95% CI 21.55 - 51.97%)
Positive Predictive Value 75.89%(95% CI 71.3 - 79.95%) 89.66%(95% CI 82.81 - 93.97%) 77.12%(95% CI 72.81 - 80.93%)
Negative Predictive Value 57.69%(95% CI 40.66 - 73.08%)
64.71%
(95% CI 54.01 - 74.11%)
75%
(95% CI 53.83 - 88.53%)
Positive Likelihood Ratio 1.38(95% CI 1.09 - 1.75)
3.79
(95% CI 2.11 - 6.82)
1.47
(95% CI 1.17 - 1.86)
Negative Likelihood Ratio 0.32(95% CI 0.16 - 0.64)
0.24
(95% CI 0.15 - 0.37)
0.15
(95% CI 0.06 - 0.38)
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diagnostic purpose while sensitivity is the impor-
tant value for the screening program to encompass
as much as possible of the positive precervical
cancer lesion patient.
In the HPV DNA, there was sensitivity of 81.25%
and specificity of 78.57%. The sensitivity was
slightly below the previous study of HPV DNA
which the sensitivity of HPV DNA ranged 86 -
97.4%.7,11-13 The discrepancy of sensitivity in this
study might be caused by the proportion of Non
NIS and NIS 1 is 67.4% while the NIS 2+ is 32.6%;
this situation could conduce the lower sensitivity
since HPV DNA reached the good sensitivity in NIS
2+ as the cut-off point.7,8,14 Moreover, there was
7.9% samples with age below the 30 years old,
where the HPV DNA is not recommended to be
performed to women < 30 years old reckoned the
high infection and regression rate in that popula-
tion. In the perspective of liquid-based cytology,
there were negative, ASCUS and LSIL result
(72.14%) compared to 27.86% of HSIL; while
Wheeler et al in 2014 reported the HPV DNA type
16 and 18 was detected respectively in 3.6% and
1.5% of negative result, 23.3% and 1.7% of ASCUS
result, 32.5% and 19.6% of LSIL result; compared
to 57.5% and 62.2% of ASCH, and 71.6% and
58.7% of result.15 Furthermore, the low
sensitivity of HPV DNA could be caused by high
false negative which might be caused by several
factors, for instance the detection assay which not
covers some type of HPV DNA, low titer or copy in
HPV, inadequacy of specimen including the DNA
quality, cytology sample with low abnormal cell,
and error of pathologist.16
The co-testing of these two screening methods
increased the sensitivity as much as 6.25% and
13.54% of liquid-based cytology and HPV DNA,
respectively. The increased sensitivity was also
accompanied with decreased false negativity of
these two screening methods. In the clinical
practice, these parameters will implicate the longer
period for the next follow-up screening. Low
specificity in liquid-based cytology and co-testing
correspond to the high false positive which might
be caused by error in cytology result. One of the
drawbacks of this study is the absence of notation
of other risk factor in medical record to exclude
the situation which might influence the false
negative and false positive; and also other
demographic factors.
CONCLUSIONS
This co-testing test improves the sensitivity as well
as negative predictive value, and positive predic-
tive value of liquid-based cytology and HPV DNA.
This result implies that this co-testing test could be
one of the options of precervical cancer lesion
screening in secondary or tertiary health center in
Indonesia reckoned of its high cost, approximately
Rp 1.200.000,-. Further studies regarding the cost
effectiveness in this co-testing test since, despite of
its high cost, it will implicate the longer period for
the next follow-up screening until 3 - 5 years
follow up.
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